Pharmacogenomic assessment of carboxylesterases 1 and 2

Genomics

Volumn 84, Issue 4, 2004, Pages 661-668

  Marsh, Sharon ^a,b   Xiao, Ming ^b,c   Yu, Jinsheng ^a,b   Ahluwalia, Ranjeet ^a,b   Minton, Matthew ^b,c   Freimuth, Robert R ^a,b   Kwok, Pui Yan ^b,c   McLeod, Howard L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREATE Pharmacogenetic Research Network   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Carboxylesterase; Irinotecan; Pharmacogenetics; Pharmacogenomics; Single nucleotide polymorphism.

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; MESSENGER RNA; UNCLASSIFIED DRUG;

AFRICA; ALLELE; AMINO ACID SEQUENCE; ARTICLE; COLON MUCOSA; COLORECTAL TUMOR; CONTROLLED STUDY; DRUG ACTIVATION; ENZYME ANALYSIS; EUROPE; GENE FREQUENCY; GENE SEQUENCE; HAPLOTYPE; HUMAN; HUMAN TISSUE; PHARMACOGENOMICS; POPULATION GENETICS; PRIORITY JOURNAL; RNA ANALYSIS; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; COLON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER;

EID: 4744340837     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygeno.2004.07.008     Document Type: Article

References (28)

1. M.R. Redinbo, S. Bencharit, and P.M. Potter Human carboxylesterase 1: from drug metabolism to drug discovery Biochem. Soc. Trans. 31 2003 620 624
2. T. Satoh, and M. Hosokawa The mammalian carboxylesterases: from molecules to functions Annu. Rev. Pharmacol. Toxicol. 38 1998 257 288
3. E.V. Pindel Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin J. Biol. Chem. 272 1997 14769 14775
4. R. Humerickhouse, K. Lohrbach, L. Li, W.F. Bosron, and M.E. Dolan Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2 Cancer Res. 60 2000 1189 1192
5. G. Xu, W. Zhang, M.K. Ma, and H.L. McLeod Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan Clin. Cancer Res. 8 2002 2605 2611
6. R.H. Mathijssen Irinotecan pathway genotype analysis to predict pharmacokinetics Clin. Cancer Res. 9 2003 3246 3253
7. M.K. Ma, and H.L. McLeod Lessons learned from the irinotecan metabolic pathway Curr. Med. Chem. 10 2003 41 49
8. P.D. Senter, K.S. Beam, B. Mixan, and A.F. Wahl Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug Bioconj. Chem. 12 2001 1074 1080
9. S.P. Sanghani Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis Clin. Cancer Res. 9 2003 4983 4991
10. W. Zhang, G. Xu, and H.L. McLeod Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis Appl. Immunohistochem. Mol. Morphol. 10 2002 374 380
11. W.E. Evans, and H.L. McLeod Pharmacogenomics-drug disposition, drug targets, and side effects N. Engl. J. Med. 348 2003 538 549
12. T. Langmann Structural organization and characterization of the promoter region of a human carboxylesterase gene Biochim. Biophys. Acta 1350 1997 65 74
13. S. Marsh, P. Kwok, and H.L. McLeod SNP databases and pharmacogenetics: great start, but a long way to go Hum. Mutat. 20 2002 174 179
14. D.J. Schaid, S.K. McDonnell, L. Wang, J.M. Cunningham, and S.N. Thibodeau Caution on pedigree haplotype inference with software that assumes linkage equilibrium Am. J. Hum. Genet. 71 2002 992 995
15. P.H. Rooney Comparative genomic hybridization and chromosomal instability in solid tumours Br. J. Cancer 80 1999 862 873
16. M.K. Leabman Natural variation in human membrane transporter genes reveals evolutionary and functional constraints Proc. Natl. Acad. Sci. USA 100 2003 5896 5901
17. J.K. Lamba Common allelic variants of cytochrome P4503A4 and their prevalence in different populations Pharmacogenetics 12 2002 121 132
18. J. Zhang The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants Pharmacogenetics 11 2001 555 572
19. X. Ke, and L.R. Cardon Efficient selective screening of haplotype tag SNPs Bioinformatics 19 2003 287 288
20. The International HapMap Project Nature 426 2003 789 796
21. M.H. Wu Characterization of multiple promoters in the human carboxylesterase 2 gene Pharmacogenetics 13 2003 425 435
22. H.L. McLeod Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals Pharmacogenetics 8 1998 195 199
23. M.M. Ameyaw, E.S. Collie-Duguid, R.H. Powrie, D. Ofori-Adjei, and H.L. McLeod Thiopurine methyltransferase alleles in British and Ghanaian populations Hum. Mol. Genet. 8 1999 367 370
24. S. Rozen, and H. Skaletsky Primer3 on the WWW for general users and for biologist programmers Methods Mol. Biol. 132 2000 365 386
25. C.M. Rose, S. Marsh, M.M. Ameyaw, and H.L. McLeod Pharmacogenetic analysis of clinically relevant genetic polymorphisms Methods Mol. Med. 85 2003 225 237
26. A.B. Incorporation (1997). Relative quantification of gene expression, User Bulletin No 2.
27. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res. 29 2001 e45
28. J. Yu, S. Marsh, R. Ahluwalia, and H.L. McLeod Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer Cancer Res. 63 2003 6170 6173